Abstract:The key problems of human immunodeficiency virus (HIV) therapy are the rapid emergence of drug-resistant mutant strains and significant cumulative drug toxicities. Therefore, there is an urgent demand for new anti-HIV agents with low toxicity and broad-spectrum antiviral potency. A series of biphenyl-substituted diarylpyrimidines with a cyanomethyl linker were designed using a molecular hybridization strategy. The cell-based anti-HIV assay showed that most of the compounds exhibited moderate to good activities against wild-type HIV-1 and clinically relevant mutant strains with a more favorable toxicity, and the enzymatic assay showed they had nanomolar activity against reverse transcriptase (RT). Compound 10p exhibited the best activity against wild-type HIV-1 with an EC50 (50% HIV-1 replication inhibitory concentration) value of 0.027 µM, an acceptable CC50 (50% cytotoxic concentration) value of 36.4 µM, and selectivity index of 1361, with moderate activities against the single mutants (EC50: E138K, 0.17 µM; Y181C, 0.87 µM; K103N, 0.9 µM; L100I, 1.21 µM, respectively), and an IC50 value of 0.059 µM against the RT enzyme, which was six-fold higher than nevirapine (NVP). The preliminary structure-activity relationship (SAR) of these new compounds was concluded. The molecular modeling predicted the binding modes of the new compounds with RT, providing molecular insight for further drug design.

Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.

Synthesis and Biological Evaluation of 4-(Hydroxyimino)arylmethyl Diarylpyrimidine Analogues As Potential Non-Nucleoside Reverse Transcriptase Inhibitors Against HIV

Design and Synthesis of a New Series of Cyclopropylamino-Linking Diarylpyrimidines As HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Design, Synthesis, and Sar of Naphthyl-Substituted Diarylpyrimidines As Non-Nucleoside Inhibitors of Hiv-1 Reverse Transcriptase

Synthesis and Anti-Hiv Activity of Aryl-2-[(4-Cyanophenyl)Amino]-4-Pyrimidinone Hydrazones As Potent Non-Nucleoside Reverse Transcriptase Inhibitors

Structural Modifications of CH(OH)-DAPYs As New HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.

Structural Modifications of Dapy Analogues with Potent Anti-Hiv-1 Activity

Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity

Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK

Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.

Synthesis and Biological Evaluation of CHX-DAPYs As HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses

Structural Modification of Diarylpyrimidine Derivatives As HIV-1 Reverse Transcriptase Inhibitors

Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs

Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.

Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors.

Synthesis and Anti-Hiv Activity Evaluation of 1-[(Alkenyl or Alkynyl or Alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones As Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Synthesis and Biological Evaluation of Pyridinone Analogues As Novel Potent HIV-1 NNRTIs.

Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.